Xeomin

Medical Uses

Xeomin is approved to treat several conditions related to muscle overactivity and other medical issues:

• Cervical Dystonia: This condition causes severe muscle contractions in the neck, leading to abnormal head positions and neck pain.
• Blepharospasm: This involves involuntary muscle spasms or twitching of the eyelids.
• Upper Limb Spasticity: It is used to treat increased muscle stiffness in the arms and hands in adults and children.
• Chronic Sialorrhea: This is a condition characterized by excessive drooling or saliva production in adults and children.

Cosmetic Uses

Xeomin is also used for aesthetic purposes in adults. It is specifically indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, which are the frown lines that appear between the eyebrows when a person scowls or frowns.

Mechanism of Action

Xeomin belongs to a class of medications known as neurotoxins. It contains incobotulinumtoxina, a purified form of the toxin produced by the bacterium Clostridium botulinum. The medication works by interfering with the communication between nerves and the muscles or glands they control.

Blocking Nerve Signals

Under normal conditions, nerves release a chemical messenger called acetylcholine. This chemical attaches to receptors on muscle cells, signaling them to tighten or contract. Xeomin prevents the release of acetylcholine from the nerve endings. Without this signal, the muscle cannot contract and remains in a relaxed state.

Effects on Different Conditions

The way Xeomin helps depends on where it is injected:

• Muscle Spasms: In conditions like cervical dystonia (neck spasms) or blepharospasm (eyelid twitching), it relaxes the overactive muscles to reduce pain and involuntary movements.
• Wrinkles: When used for cosmetic purposes, it relaxes the facial muscles that cause frown lines, smoothing the appearance of the skin.
• Saliva Production: When injected into the salivary glands, it blocks the signals that tell the glands to produce spit, which helps treat chronic drooling.

The effects of Xeomin are temporary. Over time, the nerve endings recover and regain the ability to release acetylcholine, meaning the muscle or gland activity will eventually return and repeat treatments may be necessary.

Common Side Effects

Many people experience mild side effects after receiving Xeomin. These often include:

• Pain, swelling, redness, or bruising at the injection site
• Headache
• Dry mouth
• Muscle weakness near the injection area
• Neck pain
• Eyelid drooping or swelling
• Dry eyes or blurred vision
• Tiredness or fatigue
• Runny nose or sore throat

Serious Side Effects

Seek medical help immediately if you experience any of the following serious symptoms, which can occur hours, days, or weeks after an injection:

• Difficulty breathing, talking, or swallowing
• Loss of bladder control
• Severe or unusual muscle weakness in areas far from the injection site
• Double vision or loss of vision
• Hoarseness or change in voice

Allergic Reactions

Although rare, some people may have an allergic reaction to Xeomin. Symptoms that require emergency care include:

• Rash or hives
• Itching
• Severe dizziness
• Swelling of the face, lips, tongue, or throat
• Wheezing or trouble breathing

Spread of Toxin Effect

Xeomin may cause serious side effects that can be fatal. The effects of the toxin may spread to other parts of the body away from the injection site, causing symptoms of botulism. These symptoms can occur hours, days, or weeks after an injection and include:

• Problems swallowing or breathing
• Loss of strength and muscle weakness throughout the body
• Double vision, blurred vision, or drooping eyelids
• Hoarseness or change/loss of voice
• Trouble speaking clearly
• Loss of bladder control

The risk of these symptoms is generally highest in children treated for muscle spasms, but they can also occur in adults, especially those with underlying conditions that make them susceptible.

Pre-existing Neuromuscular Disorders

Individuals with certain neuromuscular diseases, such as amyotrophic lateral sclerosis (ALS), myasthenia gravis, or Lambert-Eaton syndrome, may be at an increased risk for severe side effects. These individuals may experience significant muscle weakness or respiratory distress even at typical doses of Xeomin.

Swallowing and Breathing Difficulties

Treatment with Xeomin can result in difficulty swallowing (dysphagia) or breathing. These problems can be severe and may lead to aspiration pneumonia or death. Patients who already have breathing or swallowing problems before treatment are at the highest risk for these complications.

Hypersensitivity Reactions

Serious and immediate allergic reactions have been reported with Xeomin. These reactions can include anaphylaxis, serum sickness, hives, soft tissue swelling, and shortness of breath. Xeomin is contraindicated in anyone with a known hypersensitivity to any botulinum toxin preparation or any of the ingredients in the formulation.

Injection Site Infection

Xeomin should not be administered if there is an active infection at the planned injection site.

Ophthalmic Risks

When used to treat eyelid spasms (blepharospasm), Xeomin may cause reduced blinking. This can lead to the surface of the eye (cornea) becoming too dry, potentially resulting in ulcers or scarring. Protective eye drops, ointments, or other treatments may be necessary to protect the eye surface.

Pregnancy

There is limited data on the use of Xeomin in pregnant women. It is not known if this medication will cause harm to an unborn baby. Because the risks are not fully understood, Xeomin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

If you are pregnant or planning to become pregnant, notify your doctor before starting treatment. They can help evaluate whether the treatment is necessary during this time.

Breastfeeding

It is not known whether Xeomin passes into human breast milk or if it could affect a nursing infant. Many medications are excreted in human milk, and the effects of botulinum toxin on a breastfeeding child have not been established.

If you are breastfeeding or plan to breastfeed, you should consult with your healthcare provider. They will help you weigh the benefits of the treatment against any potential risks to your baby.

Dosage Forms

Xeomin is supplied as a white to off-white lyophilized powder for injection. It is intended for intramuscular or intraglandular use after reconstitution with a sterile, preservative-free saline solution.

Available Strengths

The medication is packaged in single-dose vials. The available strengths include:

• 50 Units
• 100 Units
• 200 Units

Because the vials do not contain a preservative, any remaining medication must be discarded after the single use. The potency units of Xeomin are specific to this product and cannot be compared to or exchanged with units of other botulinum toxin preparations.

FDA Approval and Indications

Xeomin (incobotulinumtoxina) was first approved by the U.S. Food and Drug Administration (FDA) in 2010. It is currently approved for the treatment of several conditions in adults, including:

• Chronic sialorrhea: Excessive drooling.
• Upper limb spasticity: Increased muscle stiffness in the arms.
• Cervical dystonia: Abnormal head position and neck pain.
• Blepharospasm: Involuntary blinking or eyelid twitching.
• Glabellar lines: Temporary improvement in the appearance of moderate to severe frown lines between the eyebrows.

In pediatric patients, it is approved for chronic sialorrhea in children aged 2 and older, and for upper limb spasticity in patients aged 2 to 17 years (excluding spasticity caused by cerebral palsy).

Boxed Warning

The FDA requires a boxed warning for Xeomin because the effects of the botulinum toxin may spread from the area of injection to other parts of the body. This can cause symptoms similar to botulism, which may include:

• Difficulty swallowing or breathing.
• Muscle weakness.
• Double or blurred vision.
• Loss of bladder control.
• Hoarseness or loss of voice.

These symptoms can be life-threatening and may occur hours to weeks after the injection. While the risk is highest in children treated for spasticity, it can also occur in adults treated for various conditions.

Regulatory Requirements

The FDA requires that a Medication Guide be provided to patients each time they receive a Xeomin injection to explain the potential risks. Regulatory authorities emphasize that Xeomin is not interchangeable with other botulinum toxin products; the potency units are specific to this brand and cannot be compared to or converted into units of other products.

Factors Affecting Cost

The total price of Xeomin treatment is generally determined by several variables:

• Number of Units: Xeomin is typically priced per unit. The total cost increases based on the amount of medication needed to achieve the desired effect for a specific muscle group.
• Treatment Frequency: Because the effects of the injection are temporary, repeated treatments every few months are necessary to maintain results, which adds to the long-term cost.
• Professional Fees: Since Xeomin must be administered by a healthcare professional, the total cost often includes a fee for the office visit and the injection procedure itself.

Insurance and Coverage

Insurance coverage for Xeomin varies significantly based on the reason for the prescription:

• Therapeutic Use: When used to treat medical conditions such as cervical dystonia, chronic sialorrhea (excessive drooling), blepharospasm, or upper limb spasticity, Xeomin is often covered by private insurance, Medicare, or Medicaid. Patients may need to provide documentation of medical necessity or obtain prior authorization.
• Cosmetic Use: When used for aesthetic purposes, such as treating glabellar lines (frown lines), the treatment is usually considered elective and is not covered by insurance. In these cases, patients are responsible for the full cost.

Financial Assistance Programs

The manufacturer may offer patient assistance programs or savings cards for eligible individuals to help reduce out-of-pocket expenses. Patients are encouraged to discuss these options with their healthcare provider or contact the manufacturer directly to determine eligibility for financial support.